T1	p 94 118	metastatic breast cancer
T2	p 401 447	patients with metastatic breast cancer ( MBC )
T3	p 1873 1881	patients
T4	i 124 135	doxorubicin
T5	i 139 170	pegylated liposomal doxorubicin
T6	i 332 351	doxorubicin ( DOX )
T7	i 357 396	pegylated liposomal formulation ( PLD )
T8	i 524 527	DOX
T9	i 563 566	PLD
T10	i 1393 1396	DOX
T11	i 1404 1407	PLD
T12	o 44 69	neutropenic complications
T13	o 274 306	neutropenic complications ( NC )
T14	o 698 700	NC
T15	o 720 774	absolute neutrophil count < or =1.5 x 10 ( 9 ) cells/L
T16	o 823 885	febrile neutropenia or neutropenia with a documented infection
T17	o 1254 1334	poor performance status , absolute neutrophil count < or =2.0 x 10 ( 9 ) cells/L
T18	o 1421 1424	age
T19	o 1429 1448	precycle risk score
T20	o 1671 1675	risk
T21	o 1908 1910	NC